- Home
- INFU vs IPHA Comparison
INFU vs IPHA Comparison
Compare INFU & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFU | IPHA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.1M | 119.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | INFU | IPHA |
|---|---|---|
| Price | $9.31 | $1.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $15.00 | $5.75 |
| AVG Volume (30 Days) | ★ 100.6K | 17.8K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $2.89 | $181.17 |
| Revenue Next Year | $7.66 | N/A |
| P/E Ratio | $29.77 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $4.61 | $1.18 |
| 52 Week High | $11.04 | $2.63 |
Technical Indicators
Market Signals| Indicator | INFU | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 44.64 |
| Support Level | $8.52 | $1.18 |
| Resistance Level | $9.83 | $1.88 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 43.49 | 52.94 |
Price Performance
Historical ComparisonAbout INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.